JP2017501977A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501977A5
JP2017501977A5 JP2016533067A JP2016533067A JP2017501977A5 JP 2017501977 A5 JP2017501977 A5 JP 2017501977A5 JP 2016533067 A JP2016533067 A JP 2016533067A JP 2016533067 A JP2016533067 A JP 2016533067A JP 2017501977 A5 JP2017501977 A5 JP 2017501977A5
Authority
JP
Japan
Prior art keywords
tgf
ligand
tgfbrii
receptor
capturer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016533067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501977A (ja
JP6640083B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066776 external-priority patent/WO2015077540A2/en
Publication of JP2017501977A publication Critical patent/JP2017501977A/ja
Publication of JP2017501977A5 publication Critical patent/JP2017501977A5/ja
Priority to JP2019233811A priority Critical patent/JP6952100B2/ja
Application granted granted Critical
Publication of JP6640083B2 publication Critical patent/JP6640083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016533067A 2013-11-21 2014-11-21 肺高血圧症を治療するための組成物および方法 Active JP6640083B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019233811A JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907260P 2013-11-21 2013-11-21
US61/907,260 2013-11-21
PCT/US2014/066776 WO2015077540A2 (en) 2013-11-21 2014-11-21 Compositions and methods for treating pulmonary hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233811A Division JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017501977A JP2017501977A (ja) 2017-01-19
JP2017501977A5 true JP2017501977A5 (OSRAM) 2018-04-05
JP6640083B2 JP6640083B2 (ja) 2020-02-05

Family

ID=53180397

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016533067A Active JP6640083B2 (ja) 2013-11-21 2014-11-21 肺高血圧症を治療するための組成物および方法
JP2019233811A Active JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法
JP2021156343A Active JP7474729B2 (ja) 2013-11-21 2021-09-27 肺高血圧症を治療するための組成物および方法
JP2024065676A Pending JP2024096891A (ja) 2013-11-21 2024-04-15 肺高血圧症を治療するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019233811A Active JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法
JP2021156343A Active JP7474729B2 (ja) 2013-11-21 2021-09-27 肺高血圧症を治療するための組成物および方法
JP2024065676A Pending JP2024096891A (ja) 2013-11-21 2024-04-15 肺高血圧症を治療するための組成物および方法

Country Status (9)

Country Link
US (3) US10682392B2 (OSRAM)
EP (4) EP4005585B1 (OSRAM)
JP (4) JP6640083B2 (OSRAM)
CN (2) CN120919282A (OSRAM)
AU (3) AU2014352843B2 (OSRAM)
CA (1) CA2931309C (OSRAM)
DK (2) DK3071215T3 (OSRAM)
ES (2) ES2902533T3 (OSRAM)
WO (1) WO2015077540A2 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) * 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
WO2016019368A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
ES3028883T3 (en) 2015-08-31 2025-06-20 Nat Res Council Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
CA3038526A1 (en) * 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
EP3589663A4 (en) 2017-03-02 2020-10-21 National Research Council of Canada TGF-ß RECEPTOR ECTODOMAIN FUSION MOLECULES AND THEIR USES
EP3628049B1 (en) 2017-05-04 2023-05-10 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
CA3061791A1 (en) 2017-05-12 2019-10-29 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing tgf-.beta. receptor and medicinal uses thereof
CA3077223A1 (en) 2017-09-27 2019-04-04 Epicentrx, Inc. Immunomodulatory fusion proteins
AU2019231791B2 (en) 2018-03-09 2022-08-11 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
EP3773657A4 (en) 2018-03-26 2021-12-08 Altor Bioscience LLC ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES
JP7436477B2 (ja) 2018-11-09 2024-02-21 ジエンス ヘンルイ メデイシンカンパニー リミテッド TGF-β受容体融合タンパク質医薬組成物およびその使用
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁(杭州)生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用
WO2021021528A1 (en) * 2019-07-26 2021-02-04 Board Of Trustees Of Michigan State University Methods of preventing or treating fatty degeneration of skeletal muscle
EP4021928A4 (en) * 2019-08-29 2023-09-20 NantBio, Inc. MODIFIED N-810 AND ASSOCIATED METHODS
WO2021093760A1 (zh) * 2019-11-12 2021-05-20 江苏恒瑞医药股份有限公司 含有TGF-β受体的融合蛋白及其医药用途
WO2023206188A1 (en) * 2022-04-28 2023-11-02 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR20010006534A (ko) 1997-04-18 2001-01-26 아스트루 마이클 제이 Ⅱ형 tgf-베타 수용체/면역글로불린 불변 영역 융합 단백질
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO1999065948A1 (en) 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ATE396068T1 (de) * 2002-10-14 2008-06-15 Michelin Soc Tech Wulst mit symmetrischer kraftverteilung für einen notlaufreifen
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
GB0514259D0 (en) 2005-07-12 2005-08-17 Renovo Ltd Pharmaceutical compositions
US20080009500A1 (en) * 2005-11-08 2008-01-10 Michael Kahn Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
WO2007145956A2 (en) 2006-06-05 2007-12-21 Novartis Ag USE OF TGF-β ANTAGONISTS IN TREATMENT OF PARATHYROID-RELATED DISORDERS
CN100588717C (zh) 2007-03-21 2010-02-10 中国医学科学院阜外心血管病医院 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途
CN101784539A (zh) 2007-08-22 2010-07-21 Irm责任有限公司 作为激酶抑制剂的2-杂芳基氨基嘧啶衍生物
EP2037275A1 (en) 2007-09-11 2009-03-18 F. Hoffmann-La Roche AG Differentiation of different causes of right heart failure
US8658135B2 (en) 2008-03-19 2014-02-25 National Research Council Of Canada Antagonists of ligands and uses thereof
KR101008385B1 (ko) 2008-08-01 2011-01-14 한국과학기술연구원 다환 방향족 탄화수소류 노출 여부 확인용 바이오마커 및이를 이용한 확인 방법
EP2524038A4 (en) 2010-01-12 2013-11-20 Isis Pharmaceuticals Inc MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION
EP2372364A1 (en) 2010-03-31 2011-10-05 Medizinische Hochschule Hannover Biomarker for pulmonary hypertension
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
EA201391012A1 (ru) * 2011-01-06 2014-01-30 Глэксо Груп Лимитед Лиганды, связывающиеся с рецепторами tgf-бета типа ii
US9932386B2 (en) 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
HRP20211582T1 (hr) 2011-06-03 2022-01-07 Xoma Technology Ltd. Protutijela specifična za tgf-beta
EP3530275A1 (en) * 2011-08-01 2019-08-28 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
AU2013202269A1 (en) 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
US9388412B2 (en) 2012-06-15 2016-07-12 The General Hospital Corporation Inhibitors of microRNAs that regulate production of atrial natriuretic peptide (ANP) as therapeutics and uses thereof
EP2597466A1 (en) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
HRP20240623T1 (hr) 2013-01-17 2024-08-02 Medizinische Hochschule Hannover Faktor 1 protein za uporabu u liječenju ili prevenciji bolesti
KR101346181B1 (ko) 2013-02-18 2014-01-03 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-12
KR101346132B1 (ko) 2013-02-18 2013-12-31 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-14
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) * 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
US10624929B2 (en) 2014-05-18 2020-04-21 Children's Medical Center Corporation Methods and compositions relating to exosomes
BR112016028833A2 (pt) 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
JP6910800B2 (ja) 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ, インコーポレイテッド Gdf15調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法

Similar Documents

Publication Publication Date Title
JP2017501977A5 (OSRAM)
JP2008529558A5 (OSRAM)
JP2015517489A5 (OSRAM)
JP2016539946A5 (OSRAM)
JP2015514132A5 (OSRAM)
JP2019511222A5 (OSRAM)
JP2016531144A5 (OSRAM)
JP2013533858A5 (OSRAM)
JP2019031567A5 (OSRAM)
JP2015522576A5 (OSRAM)
JP2010500399A5 (OSRAM)
JP2019151636A5 (OSRAM)
JP2016519062A5 (OSRAM)
JP2019531293A5 (OSRAM)
JP2018523668A5 (OSRAM)
JP2016505635A5 (OSRAM)
JPWO2019107530A5 (OSRAM)
JP2007500236A5 (OSRAM)
JP2012530761A5 (OSRAM)
JP2012500001A5 (OSRAM)
JP2016512213A5 (OSRAM)
JP2015110588A5 (OSRAM)
JP2017537084A5 (OSRAM)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
JP2017524682A5 (OSRAM)